The Food and Drug Administration has given ANI Pharmaceuticals the green light for colestipol hydrochloride tablets, 1 g, which are the generic of Pfizer’s Colestid. Generic Colestid is used to ...

ANI’s Colestipol Hydrochloride Tablets are the generic version of the Reference Listed Drug (RLD) Colestid ®. The current annual U.S. market for Colestipol Hydrochloride Tablets is approximately $81.3 ...

Impax has 180 days of market exclusivity on its drug. Impax Laboratories has been granted approval for its generic version of Colestid® tablets (Colestipol Hydrochloride Tablets) 1 gram ...

Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C (low-density lipoprotein, known as bad cholesterol) ...

Zydus Lifesciences has received final approval from the USFDA to market Colestipol Hydrochloride Tablets in the strength of 1mg US RLD Colestid Colestipol hydrochloride tablets are indicated as ...

Ahmedabad (Gujarat) [India], March 15 (ANI): Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market Colestipol Hydrochloride ...

Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C (low-density lipoprotein, known as bad cholesterol) in patients ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for ...

Colestipol Hydrochloride is a highly complex macro molecule drug substance with little or no systemic absorption. Zydus ANDA is only the second generic application approved by USFDA for this product.